Key Drivers
- Strong Cash Flow
- Weak Liquidity
- Elevated Valuation
AIAI Summary
BDX offers improving cash conversion and broad core-platform momentum, but at a valuation already pricing in a post-Alaris recovery, investors should wait for evidence that productivity and pricing can restore margins through the expected 2027 growth drag before becoming more constructive.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Cash Flow
- •Weak Liquidity
- •Elevated Valuation
BDX offers strong cash generation and improving leverage, but weak liquidity, high intangible exposure, and elevated valuation warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Weak short trend
- •Support rebound failed
- •Key range intact
BDX remains cautiously bearish after last month's decline, with $176.42–$177.85 support and $185.92–$186.52 resistance defining the near-term trade range.
Rebound to $185.92 quickly reversed into three lower closes
Sentiment & News
Key News Insights:
- •Trial Progress
- •Pharmacy Automation
- •Valuation Gap
BDX advanced clinical trials and pharmacy automation, supporting growth prospects despite valuation estimates below its market price.
Product and clinical momentum is constructive for BDX, though elevated valuation may limit near-term upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings